LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
$1.22
arrow_upward
+0.41%(+0.0050) 1D
Jun 3, 2:50:09 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
$1.20
High
$1.23
Low
$1.19
Mkt. cap
302.90M
Avg. vol.
1.28M
Volume
589.74K
52-wk high
$2.09
52-wk low
$0.65
EPS
-$0.28
Beta
1.53
Shares outstanding
249.30M
No. of employees
75
Open
$1.20
High
$1.23
Low
$1.19
Mkt. cap
302.90M
Avg. vol.
1.28M
Volume
589.74K
52-wk high
$2.09
52-wk low
$0.65
EPS
-$0.28
Beta
1.53
Shares outstanding
249.30M
No. of employees
75
News stories
From sources across the web
The Legal Advocate
·
5 days ago
LCTX Q1 2026 Earnings: Missed Estimates as R&D Spending Weighs on Bottom Line - Healthcare Earnings Report
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc
AI content may include mistakes. Learn more